Nilotinib Viatris (Nilotinib)

Nilotinib blocks the BCR‑ABL tyrosine kinase by binding to its ATP‑binding pocket. This inhibition stops downstream signaling pathways that drive the uncontrolled growth of leukemic cells, leading to reduced proliferation and increased apoptosis of the malignant clone.

The dosage of Nilotinib Viatris is individualized by the prescribing physician based on the patient’s disease status, prior therapies, and tolerability. Only a qualified healthcare professional should determine the appropriate dose and schedule.

Safety data for nilotinib in pregnancy and lactation are limited. It is generally contraindicated in pregnant women unless the potential benefit justifies the risk. Breastfeeding is not recommended while receiving nilotinib because the drug may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to nilotinib is imatinib, the first‑generation BCR‑ABL inhibitor. Nilotinib, a second‑generation agent, has higher potency and can be effective in patients who are resistant or intolerant to imatinib, but it may carry a different safety profile, including a higher risk of cardiovascular events.

Nilotinib should be stored at ambient temperature, below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in areas with high humidity or direct sunlight.

Nilotinib is taken orally, usually as whole tablets with a low‑fat meal. The tablets should be swallowed with water and not crushed, chewed, or split unless specifically instructed by a healthcare professional.

Serious risks include cardiovascular complications such as QT interval prolongation and arterial occlusive events, severe liver injury, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should be monitored regularly for cardiac, hepatic and dermatologic signs.

Nilotinib is contraindicated in patients with a known hypersensitivity to the drug or any of its excipients. It should also be avoided in individuals with uncontrolled cardiac arrhythmias, significant QT prolongation, or severe hepatic impairment unless a specialist determines that benefits outweigh risks.